Peer reviewed medical reference materials

 

1.      Selye, H.  “A syndrome produced by diverse nocuous agents.” Nature.  1936; 138:  32. 

2.      Cannon, W.B., J.R. Pereira.  “Increase of Adrenal Secretion in Fever”.  Proc. Natl. Acad. Sci. U.S.A.  1924; 10:  247-248.

3.      Cannon, W.B., “Stresses and strains of homeostasis”.  Am J. Med. Sci.  1935; 189:  1-4.

4.      Tattersall RB.  “Hypoadrenia or “A Bit of Addison’s Disease”.  Medical History.  1999; 43:  450-67.

5.      Heim C, EhlertU, Hellhammer DH.  “The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders”. Psychoneuroendocrinology. 2000; 25(1):  1-35.

6.      Baschetti R.  “Chronic Fatigue”.  CMAJ.  2006; 175(4):  386. 

7.      Seeman TE, Singer BH, Rowe JW et al. “Price of adaptation-allostatic load and its health consequences. MacArthur studies of successful aging”. Arch Intern Med.  1997; 157:  2259-2268. 

8.      McEwen BS.  “Physiology and neurobiology of stress and adaptation:  central role of the brain”.  Physiolo Rev.  2007; 87:  873-904.

9.      Chrousos GP.  “Organization and integration of the endocrine system”.  Sleep Med Clin. 2007; 2(2):  125-45.

10.  Tintera JW. “The hypoadrenocortical state and its management”. New York State Journal of Medicine. 1955. v. 55; (13):  1869-76.

11.  Tsigos C, Chrousos GP.  “Hypothalamic-pituitary-adrenal axis, neuroendocrine factors

12.  and stress”.  Psychosom Res.  2002; 53(4):  865-71.

13.  McEwen, BS, Seeman, T.  “Protective and damaging effects of mediators of stress. Elaborating and testing the concepts of allostasis and allostatic load”.  Ann. N Y Acad. Sci.  1999; (896):  30–47.

14.  Epel ES.  “Psychological and metabolic stress:  A recipe for accelerated cellular aging?”   Hormones.  2009; 8(1):  7-22.

15.  Parsons PA.  “The ecological stress theory of aging and hormesis:  an energetic evolutionary model”.  Biogerontology.  2007; 8:  233-42.

16.  Fries JF. “Aging, natural death, and the compression of morbidity”.  N Engl J Med.  1980; 303(3): 130-135.

17.  Campion EW.  “The oldest old”.  N Engl J Med.  1994; 330:  1819-20.

18.  Wilson JL, PhD, ND, DC.  Adrenal Fatigue:  The 21st century stress syndrome.  Presented for the American Academy of Anti-Aging, Regenerative, and Functional Medicine fellowship program, module I, Washington, D.C., July, 2008.

19.  Wilson, JL.  Adrenal fatigue: the 21st century stress syndrome.  Smart publications.  Petaluma, CA 2001.

20.  Smith S. Letter to Dr. Holland, June 1835: in Familiar Medical Quotations. P. 12-13. Ed. Strauss, Maurice B. Little Brown and Co. 1968.

21.  Harrower H.  Practical Endocrinology. 1932, 2nd ed. Harrower Laboratory. Glendale CA. 270-1.

22.  Harrower H. Practical Organotherapy. 1922, 3rd ed. Harrower Laboratory. Glendale CA. 119.

23.  Medical Annual.  Bristol, John Wright & Sons.  1896. 695.

24.  Sargent, Emile. Estudies cliniques sur l’insuffisance surrenale. A Maloine et fils.  Second edition 1920. Paris.  423.

25.  Bull. Gen. de therap., 1912 clxiii, p 881. Taken from Harrower, H. Practical Endocrinology. Second edition. Harrower Laboratory, Glendale CA.  1932.  273-4.

26.  Hoskins, RG. The tides of life: the endocrine glands in bodily adjustment. Kegan, Paul, Trench, Trubner.  London. 1933.  52.

27.  Fries, E. et.al.. A new view on hypocortisolism. Psychoneuroendocrinology. 2005; Nov 30(10):  1010-6.

28.  Demitrack, MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, Chrousos GP, Gold PW.  “Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome”. J Clin Endocrinol Metab. 1991; 73(6):  1224-34.

29.  Schultz CH, Rivers EP, Feldkamp CS, Goad EG, Smithline HA, Martin GB, Fath JJ, Wortsman J, Nowak RM.  “A characterization of hypothalamic-pituitary-adrenal axis function during and after human cardiac arrest”.  Crit Care Med.  1993 Sep; 21(9):  1339-47.

30.  Chang SS, Liaw SJ, Bullard MJ, Chiu TF, Chen JC, Liao HC.  “Adrenal insufficiency in critically ill emergency department patients: a Taiwan preliminary study”. Acad Emerg Med.  2001 Jul;8(7):  761-4.

31.  Rivers EP, Blake HC,  Dereczyk B, Ressler JA, Talos EL, Patel R,  Smithline HA, Rady MY, Wortsman J.  “Adrenal Dysfunction in Hemodynamically Unstable Patients in the Emergency Department”.   Academic Emergency Medicine.    1999; 6(6):  626-630.

32.  Nussey S, Whitehead S.  Endocrinology:  An Integrated Approach.

33.  Harvey PW, Everett DJ, Springall CJ.  Adrenal Toxicology.  Informa Health Care USA.  New York, NY.  2009.

34.  Blakemore C, Jennett S.  “Adrenal Glands”.  The Oxford Companion to the Body.  2001.

35.  Jefferies W.  Safe uses of Cortisol.  Third Edition.  Charles C Thomas, pub.  Springfield, Illinois.  2004.

36.  Mo Q, Lu SF, Simon NG.  “Dehydroepiandrosterone and its metabolites:  differential effects on androgen receptor trafficking and transcriptional activity”.  J Steroid Biochem. Mol. Biol.  2006; 99(1):  50-58.

37.  Beishuizen A, Lambertus GT,  Vermes I.  “Decreased levels of dehydroepianderosterone sulphate in sever critical illness:  a sign of exhausted adrenal reserve?” Crit Care.  2002; 6(5):  434-438.

38.  Kroboth PD, Amico JA, Stone RA, Folan M, Frye RF, Kroboth FJ, Bigos KL, Fabian TJ, Linares AM, Pollock BG, Hakala C.  “Influence of DHEA administration on 24-hour cortisol concentrations.” J Clin Psychopharmacol.  2003; 23(1):  96-9.

39.  Alhaj HA, Massey AE, McAllister-Williams RH.  “Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men:  a double-blind placebo-controlled study.” Psychopharmacology (Berl).  2006; 188(4):  541-51.

40.  Freeman S.  Biological Science.  Prentice Hall; 2nd Pkg edition.  2004.

41.  Knight RP Jr, Kornfield DS, Glaser GH, Bondy PK.  “Effects of intravenous hydrocortisone on electrolytes of serum and urine in man”.  J Clin. Endocrinol Metab.  1955; 15(2):  176-81.

42.  McAuley MM, Kenny RA, Kirkwood TT, Wilkinson DD, Jones JJ, Miller VM.  “A mathematical model of aging-related and cortisol induced hippocampal dysfunction”.  BMC Neurosci.  2009; 10(1):  26.

43.  Besedovsky HO, Del Rey A, Sorkin E.  “Integration of activated immune cell products in immune endocrine feedback circuits”.  Leukocytes and Host Defense Feedback.  Oppenheim.  New York.  1984.

44.  Yehuda R, Teicher MH, Trestman RL, Leven good RA, Siever LJ.  “Cortisol regulation in posttraumatic stress disorder and major depression: a chronobiological analysis”.  Biol Psychiatry. 1996; 40:  79–88.

45.  Deuschle M, Schweiger U, Weber B, Gotthardt U, Korner A, Schmider J, et al.  “Diurnal activity and pulsatility of the hypothalamus–pituitary– adrenal system in male depressed patients and healthy controls”.   J Clin Endocrinol Metab.  1997; 82:  234–8.

46.  Nicolson NA, van Diest R.  “Salivary cortisol patterns in vital exhaustion”.

47.  J. Psychosom Res.  2000; 49: 335–342. 

48.  Bjorntorp P. ‘‘Portal’’ adipose tissue as a generator of risk factors for cardiovascular disease and diabetes”.  Atherosclerosis 1990; 10:  493–496.

49.  Brindley DN, Rolland Y.  “Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis”.  Clin Sci.  1989; 77:  453–461.

50.  Sephton S, Sapolsky R, Kraemer H, Spiegel D.  “Diurnal cortisol rhythm as a predictor of breast cancer survival”.  J Natl Cancer Inst.  2000; 92:  994–1000.

51.  Abercrombie HC, Thurow ME, Rosenkranz MA, Kalin NH, Davidson, RJ.  “Cortisol variation in humans affects memory for emotionally-laden and neutral information”.  Behav Neurosci.  2003; 117:  505–516.

52.  Hellhammer DH, Wade S.  “Endocrine correlates of stress vulnerability”.  Psychother. Psychosom.  1993; 60:  8-17.

53.  Hauger RL, Millan MA, Lorang M, Harwood, JP, Aguilera G.  “Corticotropin-releasing factor receptors and pituitary adrenal responses during immobilization stress”.  Endocrinology.  1988; 123:  396-405.

54.  Hauger RL, Lorang M, Irwin M, Aguilera G.  “CRF receptor regulation and sensitization of ACTH responses to acute ether stress during chronic intermittent immobilization stress”.  Endocrinology.  1990; 123:  396-405.

55.  Makino S, Gold PW, Schulkin J.  “Corticosterone effects on corticotrophin-releasing hormone mRNA in the central nucleus of the amygdale and the parvocellular region of the paraventricular nucleus of the hypothalamus.” Brain Res.  1994; 640:  105-112.

56.  Yehuda R.  “Sensitization of the hypothalamic-pituitary-adrenal axis in posttraumatic stress disorder.” Ann NY Acad Sci.  1997; 821:  57-75.

57.  Heim C, Ehlert U, Hanker JP, Hellhammer DH.  “Abuse –related posttraumatic stress disorder and alterations of the hypothalamic-pituitary-adrenal axis in women with chronic pelvic pain”.  Psychosom Med.  1998; 60:  309-318.

58.  Houshyar H, Galigniana MD, Pratt WB, Woods JH.  “Differential responsivity of the hypothalamic-pituitary-adrenal axis to glucocorticoid negative-feedback and corticotrophin releasing hormone in rats undergoing morphine withdrawal:  possible mechanisms involved in facilitated and attenuated stress responses”.  J Neuroendocrinol.  2001; 13:  875-886.

59.  Griep EN, Boersma JW, Lentjes EG, Prins PA, van der Korst KK, deKloet ER.  “Function of hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain”.  J Rheumatol.  1998; 25:  1374-1381.

60.  Scott LV, Medbak S, Dinan TG.  “The low dose ACTH test in chronic fatigue syndrome and in health”.  Clin Endocrinol.  1998; 48:  733-737.

61.  Kaufman J, Birmaher B, Perel J, et al.  “The corticotrophin-releasing hormone challenge in depressed abused, depressed nonabused, and normal control children”.  Biol Psychiatry.  1997; 42:  669-679.

62.  Friedman SB, Mason JW, Hanburg DA.  “Urinary 17-hydroxycorticosteroid levels in parents of children with neoplastic disease:  a study of chronic psychological stress”.  Psychosom Med.  1963; 25:  364-376.

63.  Dutton Lm, Smolensky MH, Leach CS, Lorimor R, Hsi BP.  “Stress levels of ambulance paramedics and fire fighters”.  J Occup Med.  1978; 20:  111-15.

64.  Caplan RD, Cobb S, French JR.  “White collar work load and cortisol:  disruption of a circadian rhythm by job stress.  1979.  J Psychosom Red.  1979; 23:  181-192.

65.  Bourne PG, Rose RM, Mason JW.  “17 OHCS levels in combat.  Special forces ‘A’ team under threat of attack”.  Arch Gen Psych.  1968; 19:  135-140.

66.  Bourne PG, Rose RM, Mason JW.  “Urinary 17 OCHS levels.  Data on severn helicopter ambulance medics in combat”.  Arch Gen Psych.  1967; 17:  104-110.

67.  Nemeroff CB, Krishnan KR, Reed D, Leder R, Beam C, Dunnick NR.  “Adrenal gland enlargement in major depression”.  Arch Gen Psychiatry.  1993; 49:  384-387.

68.  Rubin RT, Phillips JJ, Sadow TF, McCracken JT.  “Adrenal gland volume in major depression:  increase during depressive episode and decrease with successful treatment”.  Arch Gen Psychiatry.  1995; 52:  213-218.

69.  Toussaint O, Michiels C, Raes M, Remacle J.   “Cellular aging and the importance of energetic factors”.  Exp Gerontol.  1995; 30:  1-22.

70.  Von Zglinicki T.  “Oxidative stress shortens telomeres”.   Trends Biochem Sci.  2002; 27:  339-44.

71.  Kultz D.  “Molecular and evolutionary basis of the cellular stress response.” Annu Rev Physiol.  2005; 67:  225-57.

72.  Rich EL, Romero LM.  “Exposure to chronic stress downregulates corticosterone responses to acute stressors”.   Am J Physiol Regulatory Integrative Comp Physiol.  2005; 288(6):  R1628-36.

73.  Chrousos G, Gold P.   “The concepts of stress and stress system disorders”.   JAMA.  1992; 267:  1244-1252.

74.  McEwen B.  “Protective and damaging effects of stress mediators”.  N Engl J Med.   1998; 338:  171-9.

75.  Gunnar MR, Vazquez DM.  “Low cortisol and flattening of expected daytime rhythm:  potential indices of risk in human development”.  Dev Psychopathol.  2001; 13(3):  515-38.

76.  Raison CL, Miller AH.  “When not enough is too much:  the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders”.   Am J Psychiatry.   2003; 160:  1554-1565.

77.  Rohleder N, Joksimovic L, Wolf JM, Kirschbaum C.  “Hypercortisolism and increased glucocorticoid sensitivity of pro-inflammatory cytokine production in Bosnian war refugees with posttraumatic stress disorder.  Biol Psychiatry.  2004; 55:  745-51.

78.  Elenkov IJ, Chrousos GP.  “Stress hormones, Th1/Th2 patters, pro/anti-inflammatory cytokines and susceptibility to disease”.  Trends Endocrinol Metab.  1999; 10:  359.

79.  Munck A, Guyre PM, Holbrook NJ.  “Physiological functions of glucocorticoids in stress and their relation to pharmacologic agents”.  Endocr Rev.  1984; 5:  25-44.

80.  Maes M, Libbrecht I, Van Hunsel F, Lin AH, De Clerck L, Stevens W, Kenis G, de Jongh R, Bosmans E, Neels H.  “The immune-inflammatory pathophysiology of fibromyalgia:  increased serum soluble gp 130, the commone signal transducer protein of various neurotrophic cytokines”.  Psychoneuroendocrinology.  1999; 24:  371-383.

81.  Patarca-Montero R, Antoni M, Fletcher MA, Klimas NG.  “Cytokine and other immunologic markers in chronic fatigue syndrome and their relation to neuropsychological factors.” Appl Neuropsychol.  2001; 8:  51-64.

82.  Thompson ME, Barkhuizen A.  “Fibromyalgia, hepatitis C infection, and the cytokine connection”.  Curr Pain Headache Rep.  2003; 7:  342-7.

83.  J.E. Bower, et al.  “Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids.” Brain, Behavior, and Immunity.  2007; 21:  251–258.

84.  Sephton S, Sapolsky R, Kraemer H, Spiegel D.   “Diurnal cortisol rhythm as a predictor of breast cancer survival”.  J Natl Cancer Inst.  2000; 92:  994–1000.

85.  Spivak B, Shohat B, Mester R, et al.  “Elevated levels of serum interleukin-1β in combat-related posttraumatic stress disorder”.  Biol Psychiatry.  1997; 42:  345-48.

86.  Delahanty DL, Dougall AL, Craig KJ, Jemkins FJ, Baum A.  “Chronic stress and natural killer cell activity after exposure to traumatic death”.  1997; 59:  467-76.

87.  DeBellis MD, Chrousos GP, Dorn LD, et al.  “Hypothalamic pituitary adrenal axis dysregulation in sexually abused girls”.  J Clin Endocrinol Metab.  1994; 78:  249-55.

88.  DeBellis MD.  “Antinuclear antibodies and thyroid function in sexually abused girls”.  J Trauma Stress.  1996; 9:  369-78.

89.  Buchwald D, Komaroff AL.  “Review of laboratory findings for patient with chronic fatigue syndrome”.  Rev Infect Dis.  1991; 13:  12-18.

90.  Hamaty D, Valentine JL, Howard CW, Wakefield V, Patten MS.  “ The plasma endorphin, prostaglandin and catecholamine profile of patients with fibrositis treated with cyclobenzaprine and placebo:  a 5 month study”.  J Rheumatol.  1989; 19:  164-8.

91.  Benedetto C.  “Eicosanoids in primary dysmenorrheal, endometriosis, and menstrual migrane”.  Gynecol Endocrinol.  1989; 3:  71-94.

92.  Geracioti Jr TD, Baker DG, Ekhator NN, West SA, Hill KK, Bruce AB, Schmidt D, Rounds-Kugler B, Yehuda R, Keck Jr PE, Kasckow JW.  “CSF norepinephrine concentrations in posttraumatic stress disorder”.  Am J Psychiatry.  2001; 158:  1227-1230.

93.  Liberzon I, Abelson JL, Flagel SB, Raz J, Young EA.  “Neuroendocrine and psychophysiologic responses in PTSD: a symptom provocation study”.  Neuropsychopharmacology.  1999; 21:  40-50.

94.  Martinez-Lavin M.  “Fibromyalgia as a sympathetically maintained pain syndrome”.  Curr Pain Headache Rep.  2004; 8:  385-9.

95.  Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer SR.  “Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia”.  Arthritis Rheum.  2000; 43:  872-880.

96.  Hellhammer J, Schlotz W, Pirke KM, Stone A.  “Allostatic load, perceived stress, and health:  a prospective study in two age groups”.  Ann NY Acad Sci.  2004; 1032:  8-13.

97.  Hart BL.  “Biological basis of the behavior of sick animals”.  Neurosci Behavior Rev.  1988; 60:  309-18.

98.  Maier SF, Watkins LR.  “Cytokines for psychologists:  implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition”.  Psychol Rev.   1998; 105:  83-107.

99.  Van Houdenhove B, Egle UT.  “Fibromyalgia:  a stress disorder?  Piecing the biopsychosocial puzzle together”.  Psychother Psychosom.  2004; 73:  267-275.

100.                      Gibson EL, Checkley S, Papadopoulos A, Poon L, Daley S, Wardle J.  “Increasd salivary cortisol reliably induced by a protein-rich midday meal”.  Psychosom Med.  1999; 61(2):  214-224.

101.                      Markus R, Panhuysen G, Tuiten A, Koppeschaar H.  “Effects of food on cortisol and mood in vulnerable subjects under controllable and uncontrollable stress”.  Physiol Behav.  2000; 70(3-4):  333-342.

102.                      Garcia-Prieto MD, Tebar FJ, Nicolas F, Larque E, Xamora S, Garaulet M.  “Cortisol secretary pattern and glucocorticoid feedback sensitivity in women from a Mediterranean area:  relationship with anthropometric characteristics, dietary intake and plasma fatty acid profile”.  Clin Endocrinol (Oxf).  2007; 66(2):  185-191.

103.                      Kirschbaum C, Bob EG, Rohleder N, Gessner C, Pirke KM, Salvador A, Hellhammer DH.  “Effects of fasting and glucose load on free cortisol responses to stress and nicotine”.  J Clin Endocrinol Metab.  1997; 82(4):  1101-1105.

104.                      MacLean CR, Walton KG, Wenneberg SR, Levitsky DK, Mandarino JP, Waziri R, Hillis SL, Schneider RH.  “Effects of the transcendental meditation program on adaptive mechanisms:  changes in hormone levels and responses to stress after 4 months of practice”.  Psychoneuroendocrinol.  1997; 22(4):  277-295.

105.                      Harte JL, Eifert GH, Smith R.  “The effects of running and meditation on beta-endorphin, corticotrophin-releasing hormone and cortisol in plasma, and on mood”.  Biol Psychol.   1995; 40(3):  251-265.

106.                      Carlson LE, Speca M, Patel KD, Goddey E.  “Mindfulness-based stress reduction in relation to quality of life, mood symptoms of stress and levels of cortisol, DHEA-S and melatonin in breast and prostate cancer outpatients”.  Psychoneuroendocrinol.  2004; 29(4):  448-474.

107.                      Udinestev SN, Shakhov VP.,   “The role of humoral factors of regenerating liver in the development of experimental tumors and the effect of Rhodiola rosea extract on this process”, Neoplasm.  38(3) (1991):323-31.

108.                      Darbinyan V, Kteyan A, et al., “Rhodiola rosea in stress induced fatigue—a double-blind cross-over study of a standardized extract SHR-5 with a repeated low dose regimen on the mental performance of healthy physicians during night duty”.  Phytomedicine.  7 (5) (Oct 2000):365-71.

109.                      Lopez-Fando A, Gomez-Serranillos MP, et al., “Lepidium peruvianum chacon restores homeostasis impaired by restraint stress.” Phytother Res.  18 (June 2004):471-4.

110.                      Sun ZY, Li FZ., “[Studies on the leaf epidermal feature of Lepidium (Brassicaceae) from

111.                      China ]”.  Zhong Yao Cai.  30 (July 2007):780-5.

112.                      Gonzales GF, Cordova A, et al., “Lepidium meyenii (Maca) improved semen parameters in adult men.” Asian J Androl.  3 (Dec 2001):301-3.

113.                      Mattioli L, Perfumi M., “Rhodiola rosea L. extract reduces stress- and CRF-induced anorexia in rats”.  J Psychopharmacol.  21 (Sep 2007):742-50.

114.                      Mattioli L, Funari C, Perfumi M., “Effects of Rhodiola rosea L. extract on behavorioural and physiological alterations induced by chronic mild stress in female rats.” J Psychopharmacol.  May, 2008.

115.                      Walker TB, Robergs RA., “Does Rhodiola rosea possess ergogenic properties?” Int J Sport Nutr Exerc Metab.  16 (June 2006):305-15.

116.                      De Bock K, Eijnde BO, et al., “Acute Rhodiola rosea intake can improve endurance exercise performance.” Int J Sport Nutr Exerc Metab.  14 (June 2004):298-307.

117.                      Winters M, “Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology.” Medline.11 (4) (Dec 2006):269-77.

118.                      Mohanty I, Arya DS, et al., “Mechanisms of cardioprotective effect of Withania somnifera in experimentally induced myocardial infarction.” Medline.  94 (4) (Apr 2004):184-90

119.                      Singh B, Chandan BK, Gupta DK, “Adaptogenic activity of a novel withanolide-free aqueous fraction from the roots of Withania som nifera Dun. (Part II).” Phytother Res. 17 (5) (May 1, 2003): 531-6.

120.                      Panda S, Kar A, “Withania somnifera and Bauhinia purpurea in the regulation of circulating thyroid hormone concentrations in female mice.” J Ethnopharmacol 67 (2) (Nov 1, 1999):  233-9.

121.                      Ahmad M, Saleem S, et al., “Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats.” Human and Experimental Toxicology 24(3) (Mar 1, 2005):  137-47.

122.                      Mishra LC, Singh BB, Dagenais S, “Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review.” Altern Med Rev.  5(4) (Aug 1, 2000):  334-46.

123.                      Kulkarni SK, Dhir A, “Withania somnifera: an Indian ginseng.” Prog Neuropsychopharmacol Biol Psychiatry.  32(5) (July 1, 2008):1093-105.

124.                      Hannan JM, Marenah L, et al., “Ocimum sanctum leaf extracts stimulate insulin secretion from perfused pancreas, isolated islets and clonal pancreatic beta-cells.” J. Endocrinol.  189(1) (Apr 1, 2006):127-36.

125.                      Subramanian M, Chintalwar GJ, “Antioxidant and radioprotective properties of an Ocimum sanctum polysaccharide.” Redox Rep.  10 (5) (Jan 1, 2005):257-64.

126.                      Geetha RK, Vasudevan DM, “Inhibition of lipid peroxidation by botanical extracts of Ocimum sanctum: in vivo and in vitro studies.” Life Sci.  76 (1) (Nov 19, 2004): 21-8.

127.                      Sood S, Narang D, “Effect of Ocimum sanctum Linn. On cardiac changes in rats subjected to chronic restraint stress.” J Ethnopharmacol.  108 (3) (Dec 6, 2006): 423-7.

128.                      Gupta S, Mediratta PK, et al., “Antidiabetic, antihypercholesterolaemic and antioxidant effect of Ocimum sanctum (Linn) seed oil.” Indian J Exp Biol.  44(4) (Apr 1, 2006): 300-4.

129.                      Mediratta PK, Sharma KK, and Singh S, “Evaluation of immunomodulatory potential of Ocimum sanctum seed oil and its possible mechanism of action.” J Ethnopharmacol.  80(1) (Apr 1, 2002): 15-20.

130.                      Shokeen P, Ray K, et al. “Preliminary studies on activity of Ocimum sanctum, Drynaria quercifolia, and Annona squamosa against Neisseria gonorrhoeae.” Sex Transm Dis. 32(2) (Feb 1, 2005): 106-11.

131.                      Singh S, Majumdar DK, “Effect of Ocimum sanctum fixed oil on vascular permeability and leucocytes migration.” Indian J Exp Biol.  37(11) (Nov 1, 1999):1136-8.

132.                      Armanini D, et al., “Licorice” Steroids.  69 (11-12) (Oct-Nov 2004):763-6.

133.                      Haraguchi H, Yoshida N, et al., “Protection of mitochondrial functions against oxidative stresses by isoflavans from Glycyrrhiza glabra.” J Pharm Pharmacol.  52 (2) (Feb 1, 2000): 219-23.

134.                      Dhingra D, Parle M, and Kulkarni SK, “Memory enhancing activity of Glycyrrhiza glabra in mice.” J Ethnopharmacol.  91 (Apr 2004): 361-5.

135.                      Gupta VK, Fatima A, et al., “Antimicrobial potential of Glycyrrhiza glabra roots.” J Ethnopharmacol.  116 (Mar 2008): 377-80.

136.                      Sheela ML, Ramakrishna MK, “Angiogenic and proliferative effects of the cytokine VEGF in Ehrlich ascites tumor cells is inhibitied by Glycyrrhiza glabra.” Int Immunopharmacol.  6 (Mar 2006): 494-8.

137.                      Dhingra D, Shamra A, “Antidepressant-like activity of Glycrrhiza glabra L. in mouse models of immobility tests.” Prog Neuropsychopharmacol Biol Psychiatry.  30 (May 2006): 449-54.

138.                      Lishamov IuB, et al. “Ginseng” Biull Eksp Biol Med.  98 (8) (Aug 1984):199-200.

139.                      Gaffney BT, et al. “Ginseng” Life Sci. 70 (4) (Dec 14, 2001):431-42.

140.                      Deyama T, Nishibe S, Nakazawa Y, “Ginseng” Acta Pharmacol Sin. 22(12) (Dec 2001): 1057-70.

141.                      Rao GM, Karanth KS, “Neuropharmaological activity of Herpestis monniera” Fitoterapia.  63(5) (1992): 399-404.

142.                      Visavadiya NP, Narasimhacharya AV, “Hypocholesterolaemic and antioxidant effects of Glycyrrhiza glabra (Linn) in rats.” Mol Nutr Food Res.  0(11) (Nov 1, 2006): 1080-6.

143.                      Fatima A, Gupta VK, et al. “Antifungal activity of Glycyrrhiza glabra extracts and its active constituent glabridin.” Phytother Res.  (Jan 23, 2009).

144.                      Fiore C, Eisenhut M, et al. “Antiviral effects of Glycyrrhiza species.” Phytother Res.  22(2) (Feb 1, 2008): 141-8.

145.                      Bafna PA, Balaraman R, “Anti-ulcer and anti-oxidant activity of pepticare, a herbomineral formulation.” Phytomedicine. 12(4) (Apr 1, 2005): 264-70.

146.                      Kamisoyama H, Honda K, et al. “Investigation of the anti-obesity action of licorice flavonoid oil in diet-induced obese rats.” Biosci Biotechnol Biochem.  72 (12) (Dec 1, 2008): 3225-31.

147.                      Deyama T, Nishibe S, Nakazawa Y, “Constituents and pharmacological effects of Eucommia and Siberian ginseng.” Acta Pharmacol Sin.  2(12) (Dec 1, 2001): 1057-70.

148.                      Kalman DS, Feldman S, et al., “Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial.” Nutr J.  7 (Jan 1, 2008): 11.

149.                      Chang WC, Yu YM, et al., “Inhibitory effect of Magnolia officinalis and lovastatin on aortic oxidative stress and apoptosis in hyperlipidemic rabbits.” J Cardiovasc Pharmacol.  7(3) (Mar 1, 2006): 463-8.

150.                      Horigome H, Homma M, et al., “Magnolol from Magnolia officinalis inhibits 11beta-hydroxysteriod dehydrogenase without increases of corticosterone and thymocyte apoptosis in mice.” Planta Med.  67(1) (Feb 1, 2007): 33-7.

151.                      Rai D, Bhatia G, et al., “Adaptogenic effect of Bacopa moniera (Brahmi).” Pharmacol Biochem Behav.  75(4) (Jul 1, 2003): 823-30.

152.                      Kuo YC, Tsai WJ, et al., “Cordyceps sinensis as an immunomodulatory agent.” Am J Chin Med.  24(2) (Jan 1, 1996): 111-25.

153.                      Chiou WF, Chang PC, et al., “Protein constituent contributes to the hypotensive and vasrelaxant activities of Cordyceps sinensis.” Life Sci.  66 (14) (Feb 25, 2000): 1369-76.

154.                      Zhu JS, Halpern GM, Jones K, “The scientific rediscovery of a precious ancient Chinese herbal regimen: Cordyceps sinensis: part II.” J Altern Compl Med.  4(4) (Dec 1, 1998): 429-57.

155.                      Panossian A, Wikman G.  “Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity”.  Curr Clin Pharmacol.2009 Sep;4(3):198-219.

156.                      Narita K, Kunema T, Narita S. “Effects of pantethine on the reserve function of the adrenal cortex in nephrosis syndrome”.  Horumon To Rinsho.  1970 Jun;18(6):505-8.

157.                      Onuki M, Susawa A.  “Effect of pantethine on the function of the adrenal cortex.  2.  Clinical experience using pantethine in cases under steroid hormone treatment”.  Horumon To Rinso.  1970 Nov; 18(11):937-40.

158.                      Vinogradov VV, Tarasov IuA, Tishin VS, Bogdanovich VI, Spas VV.  “Thiamine prevention of the corticosteroid reaction afer surgery”.  Probl Endokrinol.  1981 May-Jun; 27(3):11-6. [Article in Russian]

159.                      Shelygina NM, Spivak RIa, Zaretskii MM, Panichkina VI, Gusiatinskaia VM.  “Influence of vitamins C, Bl, and B6 on the diurnal periodicity of the glucocorticoid function of the adrenal cortex in patients with atherosclerotic cardiosclerosis”.  Vopr Vitan.  1975 Mar-Apr; (2):25-9. [Article in Russian]

160.                      Fidanaza A, Floridi S, Lenti L.  “Panthenol and glucocorticoids”.  Bollettino-Soc Ital Biol Sperimentale.  1981; 57(18):  1869-1872.

161.                      Peters EM, Anderson R, Therone AJ.  “Attenuation of increase in circulating cortsiol and enhancement of the acute phase protein response in vitamin C-supplemented ultramarathon runners”.  Int J Sports Med.  2001; 22(2):  120-126.

162.                      Patak P, Willenberg HS, Bornstein SR.  “Vitamin C is an important cofactor for both adrenal cortex and adrenal medulla”.  Endo Res.  2004; 30(4):  871-875.

163.                      Golf SW, Bender S, Gruttner J.  “On the significance of magnesium in extreme physical stress”.  Cardiovas Drugs Therap.  1998; 12:  197-202.

164.                      Stout SC, Ownes MJ, Nemeroff CB.  “Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment”.  J Pharmacol Exp Ther. 2002 Mar; 300(3):1085-92.

165.                      Jensen JB, Jessop DS, Harbuz MS, Mørk A, Sánchez C, Mikkelsen JD.  “Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats”.  Neuroendocrinol. 1999 Jun; 11(6):465-71.

166.                      Kanat M, Serin E, Tunckale A, Yildiz O, Sahin S, Bolayirli M, Arinc H, Dirican A, Karagoz Y, Altuntas Y, Celebi H, Oguz A.  “Multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study)”. J Endocrinol Invest.  2009 Nov; 32(10):852-6.

167.                      Bouma EM, Riese H, Ormel J, Verhulst FC, Oldehinkel AJ.  “Adolescents' cortisol responses to awakening and social stress; effects of gender, menstrual phase and oral contraceptives. The TRAILS study”. Psychoneuroendocrinology. 2009 Jul; 34(6):884-93. Epub 2009 Feb 4.

168.                      Oelkers W.  “Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone”.  Eur J Contracept Reprod Health Care. 2000 Dec; 5 Suppl 3:17-24.

169.                      Kuhlmann S, Wolf OT.  Cortisol and memory retrieval in women: influence of menstrual cycle and oral contraceptives.  Psychopharmacology (Berl). 2005 Nov; 183(1):65-71.

 

 

 

Be Healthy